Type 1 diabetes (T1D) is a chronic autoimmune condition in which the immune system mistakenly attacks and destroys the insulin-producing beta cells of the pancreas. This loss of insulin production leads to dangerously high blood glucose levels, requiring lifelong insulin therapy and careful disease management. While insulin therapy is effective at managing symptoms, it does not address the underlying autoimmune destruction. In recent years, immune modulation therapies have emerged as a promising strategy to alter the course of T1D by re‑educating or suppressing the aberrant immune response. At the forefront of this research is the Juvenile Diabetes Research Foundation (JDRF), an organization that has invested more than $2.5 billion in T1D research since its founding. This article explores the role of JDRF in advancing immune modulation therapies, the scientific approaches being pursued, and what the future may hold for millions of people living with T1D worldwide.

Understanding Type 1 Diabetes

Type 1 diabetes accounts for approximately 5–10% of all diabetes cases and affects an estimated 1.45 million people in the United States alone, with incidence rising globally. It typically manifests in childhood or adolescence, though it can occur at any age. The autoimmune attack is driven by autoreactive T cells that recognize pancreatic beta cell antigens, leading to progressive beta cell loss. By the time symptoms appear—excessive thirst, frequent urination, weight loss—most beta cells have already been destroyed. Genetic factors, such as certain HLA haplotypes, and environmental triggers, including viral infections, are thought to contribute to disease initiation.

The standard of care has remained largely unchanged for decades: exogenous insulin delivered via injections or pumps, combined with continuous glucose monitoring. While these treatments have improved quality of life, they do not stop the autoimmune process. People with T1D still face a lifelong risk of acute complications (hypoglycemia, diabetic ketoacidosis) and chronic complications (nephropathy, retinopathy, cardiovascular disease). This persistent unmet need has motivated researchers to look beyond symptom management and toward interventions that can modify the disease itself.

Immune Modulation: A Paradigm Shift in T1D Treatment

Immune modulation therapies aim to restore immune tolerance to pancreatic beta cells, either by dampening the autoimmune attack or by boosting protective regulatory mechanisms. Unlike broad immunosuppression—which leaves patients vulnerable to infections and malignancies—immune modulation is designed to be selective, targeting only the pathological components of the immune system. The ultimate goal is to prevent the onset of T1D in at‑risk individuals, preserve remaining beta cell function in newly diagnosed patients, or even induce long‑term remission.

JDRF has been instrumental in championing this paradigm shift. Through its strategic research portfolio, the foundation supports a wide range of immune‑modulating approaches, from biologic agents that block inflammatory signals to cell therapy products that deploy regulatory T cells (Tregs). The hope is that one or more of these strategies will prove safe and effective enough to become a standard part of T1D care.

Key Immune Modulation Approaches

Several distinct categories of immune modulation are under active investigation. Each targets a different arm of the immune system, but all share the common objective of halting or reversing beta cell destruction.

  • Cytokine‑Targeted Therapies: Cytokines are signaling proteins that coordinate immune responses. In T1D, pro‑inflammatory cytokines such as tumour necrosis factor‑alpha (TNF‑α), interleukin‑1β (IL‑1β), and interleukin‑6 (IL‑6) contribute to beta cell death. Drugs that neutralize these cytokines—already approved for autoimmune diseases like rheumatoid arthritis—are being repurposed for T1D. For example, a recent phase 2 trial of baricitinib, a JAK inhibitor that blocks multiple cytokine pathways, showed a reduction in the rate of C‑peptide decline (a marker of residual insulin production) in newly diagnosed adults. JDRF funded early feasibility studies of this agent.
  • Cell‑Based Therapies: Regulatory T cells (Tregs) are a specialized subset of T cells that suppress autoreactive immune cells. In T1D, Treg function is often impaired. Polyclonal Treg adoptive transfer—infusing expanded Tregs collected from a patient’s own blood—has shown safety and preliminary efficacy in preserving beta cell function. JDRF has supported the development of Treg manufacturing protocols and the first‑in‑human clinical trials at institutions such as the University of California, San Francisco. A newer approach uses chimeric antigen receptor (CAR) Tregs engineered to recognize beta cell antigens with greater precision.
  • Antigen‑Specific Therapies: Rather than broadly suppressing the immune system, antigen‑specific therapies aim to induce tolerance to particular beta cell proteins. These include peptide‑based vaccines that present fragments of insulin or GAD65 to the immune system in a way that promotes regulatory rather than inflammatory responses. The DiaPep277 trial (using a heat‑shock protein peptide) initially showed promise but later failed in phase 3; however, newer formulations using liposomal delivery are being tested. JDRF co‑funded a study of intranasal insulin to induce tolerance, and results from the global INNODIA consortium—heavily supported by JDRF—are guiding the development of next‑generation antigen‑specific strategies.

JDRF: A Catalyst for Change

History and Mission

Founded in 1970 by parents of children with diabetes, JDRF (formerly the Juvenile Diabetes Research Foundation) is the world’s largest nonprofit funder of T1D research. Its mission is to accelerate life‑changing breakthroughs to cure, prevent, and treat T1D and its complications. Over five decades, the organization has evolved from a grassroots advocacy group into a sophisticated research engine that shapes the global scientific agenda.

JDRF’s impact extends far beyond funding grants. It convenes scientific workshops, establishes industry partnerships, and collaborates with regulatory agencies to streamline the path from laboratory discoveries to clinical trials. The foundation’s Research Portfolio Development process systematically identifies gaps in the research landscape and directs resources to the most promising opportunities. Immune modulation has been a top priority area for over a decade, with dedicated funding streams and a full‑time research team focused on immunotherapy.

Strategic Investments in Immune Modulation

JDRF’s investment in immune modulation is multifaceted. The foundation directly funds academic researchers through its Career Development Awards, Innovative Grants, and Strategic Research Agreements. It also co‑funds major consortiums like the Immune Tolerance Network (ITN) and the Type 1 Diabetes TrialNet, which carry out large‑scale clinical trials of immune‑modulating agents.

For example, TrialNet’s teplizumab study demonstrated that a 14‑day course of an anti‑CD3 monoclonal antibody could delay the onset of clinical T1D by a median of two years in high‑risk individuals. This landmark result, published in 2019, marked the first time any therapy had been shown to prevent T1D. Teplizumab (now marketed as Tzield) received FDA approval in late 2022 for delaying stage 3 T1D in individuals aged 8 years and older. JDRF played a critical role in funding the preclinical development of anti‑CD3 antibodies and in advocating for the trial’s regulatory pathway.

Beyond teplizumab, JDRF has supported trials of abatacept (CTLA‑4‑Ig), rituximab (anti‑CD20), alefacept (anti‑CD2), and low‑dose anti‑thymocyte globulin (ATG). While many of these agents showed only transient benefits, they have provided essential proof‑of‑concept that immune modulation can preserve beta cell function. JDRF uses the results to refine the next generation of therapies—for instance, combining agents that target different immune pathways to achieve more durable tolerance.

Advocacy and Policy Work

Scientific progress alone is insufficient. JDRF also engages in legislative and regulatory advocacy to ensure that promising therapies reach patients. This includes pushing for increased funding for the National Institutes of Health (NIH) and the Special Diabetes Program, which provides targeted resources for T1D research. JDRF representatives regularly testify before Congress and meet with FDA officials to discuss expedited review pathways for immune modulation treatments.

The foundation also works with insurers and healthcare systems to ensure that new therapies are accessible. For expensive biologic drugs or cell therapies, coverage decisions can make or break a product’s commercial viability. JDRF’s Access and Reimbursement team collaborates with manufacturers and payers to build evidence of long‑term value, helping to justify the upfront cost of immune modulation.

Clinical Progress and Emerging Therapies

Recent Clinical Trials and Results

The pace of clinical development in immune modulation for T1D has accelerated sharply. In addition to teplizumab, several other agents have shown encouraging results in phase 2 and phase 3 trials.

  • Teplizumab (anti‑CD3): As noted, this agent delays disease onset and, in newly diagnosed patients, preserves C‑peptide for up to two years. The PROTECT study (also funded by JDRF) is currently evaluating a more convenient subcutaneous formulation.
  • Baricitinib (JAK inhibitor): The BANDIT trial recently reported that baricitinib slowed the decline of beta cell function in recent‑onset T1D adults over 48 weeks. JDRF provided early support for this repurposing study.
  • Low‑dose anti‑thymocyte globulin (ATG): The Immune Tolerance Network’s STOP‑T1D trial found that a single low dose of ATG combined with granulocyte‑colony stimulating factor (G‑CSF) preserved C‑peptide for two years, but with significant side effects. JDRF is now funding studies to optimize dosing regimens.
  • Oral insulin: TrialNet’s long‑running oral insulin prevention trial did not meet its primary endpoint in the overall cohort, but subgroup analyses in individuals with high levels of insulin autoantibodies suggested a modest effect. JDRF continues to support a second prevention trial targeting this subgroup.

These examples underscore that immune modulation is not a one‑size‑fits‑all solution. Patient age, disease duration, genetic background, and immune status all influence treatment response. JDRF is investing heavily in biomarker development—measuring autoantibody profiles, T cell reactivity, and cytokine signatures—to identify who will benefit most from which therapy.

Challenges and Considerations

Despite the promise, immune modulation for T1D faces several hurdles. Safety remains paramount: even selective immunotherapies can cause unintended infections or autoimmune reactions. For instance, teplizumab treatment leads to transient lymphopenia and can trigger a cytokine release syndrome requiring monitoring. Balancing efficacy with safety is especially delicate when treating children or adolescents.

Another challenge is durability. Many treatments only delay progression rather than induce permanent tolerance. Combination therapies that pair immune modulation with beta cell regeneration (e.g., stem‑cell‑derived islets) are being explored, but they add complexity and cost. JDRF has launched a combination therapy initiative to systematically test such approaches.

Finally, the economic and regulatory environment can slow adoption. Developing a new biologic drug costs billions of dollars, and many companies are hesitant to invest in T1D given the relatively small market compared to type 2 diabetes. JDRF’s Venture Fund and partnerships with pharmaceutical firms help de‑risk early‑stage development, encouraging industry to participate.

The Road Ahead

JDRF envisions a future in which T1D is no longer a lifelong sentence of insulin dependence. Immune modulation therapies, combined with advances in beta cell replacement and closed‑loop insulin delivery, could allow people with T1D to live without constant worry about blood sugar levels. The foundation’s strategic plan, “Accelerating Breakthroughs,” sets ambitious targets: by 2030, JDRF aims to have at least one immune‑modulating therapy approved for prevention or early‑stage treatment, and to have established biomarkers that enable precision immunotherapy.

To achieve this, JDRF continues to expand its global reach. The JDRF International network now funds research in more than 20 countries, leveraging expertise from Europe, Australia, and Asia. Collaborations with organizations like the Helmsley Charitable Trust, the Leona M. and Harry B. Helmsley Charitable Trust, and the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) multiply the impact of every dollar spent.

For the millions of people living with T1D, the progress in immune modulation offers genuine hope. While no therapy yet cures the disease, the trajectory is unmistakably positive. A decade ago, the concept of delaying T1D onset was theoretical. Today, teplizumab is a clinically available option. JDRF’s unwavering commitment—backed by rigorous science, strategic funding, and relentless advocacy—has made this transformation possible. The next decade will likely see even more breakthroughs as researchers combine knowledge from immunology, genetics, bioengineering, and data science.

As JDRF often states, the end of T1D begins with research. And with immune modulation therapies increasingly entering clinical practice, the foundation’s vision of a world without T1D has never been closer.